Delenex Therapeutics closes CHF 7.3 (USD 8.0) Million Series A3 Financing

New capital will support a phase 2a clinical trial in topical treatment of psoriasis and advance additional PENTRA^(R)Bodies to clinical-stage of development.

Schlieren/Zurich, Switzerland - October 29, 2013 - Delenex Therapeutics AG, a biotechnology company developing topical and local treatments for dermatologic diseases using its proprietary PENTRA^(R)Bodies, today announced the closing of a CHF 7.3 (USD 8.0) Million Series A3 round. All existing venture investors, HBM Ventures, Novo A/S, SV Life Sciences, BioMedinvest and Venture Incubator participated in the round. In addition, minority investors also participated.

These proceeds will primarily be used to:

1. finish a phase 2a clinical study using the anti-TNF PENTRA^(R)Body DLX105 in psoriasis,  
with data expected in mid-2014,

2. advance the development of PENTRA^(R)Bodies for the treatment of certain dermatologic
diseases towards clinical development, and

3. exploit the PENTRA^(R) antibody and technology platform for the generation of novel products.

This financing round brings Delenex' total capital raised since inception to CHF 37.6 million.

Executive Chairman Dr. Thomas Hecht said, 'The findings of our ongoing psoriasis program and progress of earlier-stage projects provide a strong rationale for supporting additional investments in Delenex' pipeline. We are confident that we can strengthen our dermatology franchise and also explore additional therapeutic areas with this continued financial support by our investors.' CFO Jakob Schlapbach mentioned, 'We are very pleased that all prior major investors engaged in this financing round on their pro rata basis. This shows the strong commitment of our investors to the promise of our products and platform.'

About Delenex Therapeutics AG

Delenex is a privately-held biopharmaceutical company focused on the development of locally or topically applied antibody therapeutics. Thereby Delenex aims at extending the
benefits of proven antibody therapeutics to a much larger number of patients. Delenex' proprietary PENTRA^(R) platform will deliver such novel, potent and safe antibody therapeutics that are well suited for local/topical application.

Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company).

For further information, please contact:
Jakob Schlapbach
Chief Financial Officer
Phone: +41 44 730 5180
E-mail: jakob.schlapbach@delenex.com
Website: http://www.delenex.com